Ascletis Pharma Inc. (ASCLETIS-B) reported a marginal expansion of its share base for April 2026, driven solely by employee option exercises while authorised capital and treasury share levels stayed unchanged.
Key developments
1. Issued share increase • 240,525 new ordinary shares were issued on option exercises under the 2019 Share Option Scheme, lifting the outstanding share count (excluding treasury shares) to 1.06 billion (1,061.37 million) as of 30 April 2026 from 1.06 billion (1,061.13 million) a month earlier. • The 0.02 % dilution keeps total issued shares (including treasury stock) at 1.07 billion.
2. Fund inflow from options • Proceeds from the exercised options totalled HKD 0.42 million, implying an average exercise price of roughly HKD 1.76 per share.
3. Treasury shares & buy-backs • Treasury stock held steady at 7.08 million shares, representing about 0.66 % of total issued capital. • Separately, 5.79 million shares previously repurchased for cancellation (0.54 % of total issued shares) remained uncancelled at month-end, reflecting ongoing execution of the company’s buy-back programme initiated in April 2025 and continued through December 2025.
4. Authorised capital unchanged • Authorised share capital stayed at 7.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to authorised capital of USD 0.70 million. Current issued shares utilise roughly 15 % of this limit.
5. Public float intact • Ascletis confirmed compliance with the Hong Kong Stock Exchange’s minimum 25 % public float requirement as at 30 April 2026.
Implications
The negligible 0.02 % issuance suggests limited dilution for existing shareholders, while option exercises signal employee confidence and provide modest capital. Concurrent share-repurchase activities—still pending formal cancellation—indicate management’s commitment to capital management and shareholder returns. With ample headroom in authorised capital and continued adherence to listing rules, Ascletis maintains flexibility for future equity initiatives.